Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
Stargardt disease (STGD) is a monogenic disease characterized by retinal dystrophy and macular degeneration that results in progressive loss of vision. In contrast to many other forms of macular degeneration or retinal dystrophy, STGD typically strikes patients in early adulthood. Despite the severity of the disease and the tremendous burden it inflicts on patients, there are no therapies approved to treat STGD. Although VEGF inhibitors (Avastin, Eylea, Lucentis) are prescribed off-label on rare occasions, there is no clinical evidence from prospective trials that the agents are effective in STGD. However, several therapies with novel mechanisms of action are in development to treat STGD and, if efficacious, stand to capitalize on the immense unmet need for effective therapies in this space.
- What are the key areas of unmet need and opportunity in the STGD market?
- What is the approximate size of the diagnosed STGD population in the United States? How are pediatric and adult cases of STGD segmented by visual acuity?
- What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?
- How does each current and future player influence the market and how will this change in the future?
- What are the key drivers and limiters of the STGD market?
- Geography: United States
- Primary Research: Three KOL interviews in April 2019
- Key Companies Covered: Sanofi, Astellas, Roche, Regeneron, Novartis, Acucela, Alkeus, Iveric
- Key Drugs Covered: Lucentis, Eylea, Avastin, ASP-7317, Zimura (avacincaptad pegol), ALK-001, SAR-422459
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Stargardt Disease - Executive Insights - Executive Insights (US)
Author(s): Ian Love; Narendra Parihar
Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets.
He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his B.S. in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.